Search Results - "Bousiou, Z"

Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience by Gavriilaki, E, Mallouri, D, Bousiou, Z, Demosthenous, C, Vardi, A, Dolgyras, P, Batsis, I, Stroggyli, E, Karvouni, P, Masmanidou, M, Gavriilaki, M, Bouinta, A, Bitsianis, S, Kapravelos, N, Bitzani, M, Vasileiadou, G, Yannaki, E, Sotiropoulos, D, Papagiannopoulos, S, Kazis, D, Kimiskidis, V, Anagnostopoulos, A, Sakellari, I

“…Commercially available anti-CD19 chimeric antigen receptor T cells (CARΤ cells) have offered long-term survival to a constantly expanding patient population…”
Get full text

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3‐MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION by Gavriilaki, E., Papalexandri, A., Mallouri, D., Batsis, I., Vardi, A., Bousiou, Z., Demosthenous, C., Panteliadou, A., Spyridis, N., Karavalakis, G., Touloumenidou, T., Masmanidou, M., Pistiolas, G., Mouladeniou, F., Vadikoliou, C., Lalayanni, C., Yannaki, E., Anagnostopoulos, A., Sakellari, I.

Get full text

Secondary Malignancies in Multiple Myeloma by Vadikoliou, C, Malouri, D, Kaliou, M, Bousiou, Z, Lalayianni, C, Athanasiadou, A, Spanoudakis, E, Kokoviadou, K, Katodritou, I, Garypidou, V, Kiriazis, G, Saloum, R, Sakellari, I, Anagnostopoulos, A

Get full text

Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL by Papadopoulou, A., Karavalakis, G., Papadopoulou, E., Xochelli, A., Bousiou, Z., Vogiatzoglou, A., Papayanni, P.G., Georgakopoulou, A., Giannaki, M., Stavridou, F., Vallianou, I., Kammenou, M., Varsamoudi, E., Papadimitriou, V., Giannaki, C., Sileli, M., Stergiouda, Z., Stefanou, G., Kourlaba, G., Triantafyllidou, M., Siotou, E., Karaglani, A., Zotou, E., Chatzika, G., Boukla, A., Apostolou, D., Pitsiou, G., Morfesis, P., Bartzoudis, D., Imprialos, K., Karampatakis, T., Kapravelos, N., Bitzani, M., Theodorakopoulou, M., Serasli, E., Sakellari, I., Fylaktou, A., Tryfon, S., Anagnostopoulos, A., Yannaki, E.

Get full text

PB2338 LONG‐TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN SEVERE APLASTIC ANEMIA: PNH CLONES MATTER by Sakellari, I., Gavriilaki, E., Mallouri, D., Batsis, I., Chatzikonstantinou, T., Vardi, A., Bousiou, Z., Demosthenous, C., Masmanidou, M., Douka, V., Syrigou, A., Sotiropoulos, D., Constantinou, V., Anagnostopoulos, A.

“…Background: Severe aplastic anemia (SAA) is a disease of young people, in which allogeneic hematopoietic cell transplantation (HCT) provides curative therapy…”
Get full text